Longriver Investment Partners
Overview
An independent investment manager based in Hong Kong that runs a global equity strategy with a focus on value investing principles.
Portfolio Companies
7
Website
longriverinv.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ronovo Surgical | Aug 2023 | Series B Extension | Co-investor |
| Rona Therapeutics | Jul 2024 | Series A Extension | Lead |
| Sironax | Aug 2022 | Series B | Co-investor |
| Allorion Therapeutics | Mar 2023 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Longriver Investment Partners based?
Headquarters information for Longriver Investment Partners is not publicly available.
When was Longriver Investment Partners founded?
Founding year information for Longriver Investment Partners is not publicly available.
How many portfolio companies does Longriver Investment Partners have?
Longriver Investment Partners has 7 portfolio companies in Caplight's dataset.
What are some companies in Longriver Investment Partners's portfolio?
Portfolio companies visible on Caplight include Ronovo Surgical, Rona Therapeutics, Sironax, Allorion Therapeutics.
What was Longriver Investment Partners's most recent investment shown here?
Longriver Investment Partners's most recent investment in this portfolio sample was in Rona Therapeutics in 2024.
What sectors does Longriver Investment Partners focus on?
Longriver Investment Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Longriver Investment Partners focus on?
Longriver Investment Partners typically invests at the Mid stage.
What is Longriver Investment Partners's AUM?
Longriver Investment Partners's assets under management are estimated between $385.0M and $400.0M.